# US 2025/0195419 A1 · Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0195419 A1
- Document ID: US20250195419A1
- Status: Published application
- Kind: A1
- Application number: 18/999,928
- Filed: 2024-12-23
- Published: 2025-06-19
- Earliest claimed: 2017-11-07
- Assignees: Rani Therapeutics, LLC
- Applicants: Rani Therapeutics, LLC
- Inventors: Mir Imran; Sara Ansaloni; Radhika Korupolu; Joel M. Harris; Mir Hashim
- Web page: https://patentgrep.com/patent/US20250195419A1

## CPC

- A61K 9/0065: {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- A61B 5/4839: {combined with drug delivery}
- A61B 5/6861: {Capsules, e.g. for swallowing or implanting}
- A61B 5/7285: {for synchronizing or triggering a physiological measurement or image acquisition with a physiological event or waveform, e.g. an ECG signal}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0097: {Medicinal compositions released by microdevices, e.g. microelectromechanical systems [MEMS], microdevices comprising chips or microdevices on silicon}
- A61K 38/37: Factors VIII
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61M 5/14276: {specially adapted for implantation}
- A61M 5/148: flexible (A61M5/155 takes precedence)
- A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure}
- A61B 5/02035: {Determining blood viscosity}
- A61B 2562/0247: Pressure sensors
- A61M 2005/14284: {with needle insertion means}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.

## Claims

### Claim at position 1

1-51. (canceled)

### Claim 52

A method for treating a clotting disorder in a patient, the method comprising:
administering to a patient in need thereof by swallowing a swallowable device, the swallowable device comprising a swallowable capsule, a tissue penetrating member disposed in the capsule, a liquid therapeutic agent preparation comprising a clotting factor disposed in the capsule, and an actuation mechanism operably coupled to the tissue penetrating member;
wherein the tissue penetrating member is advanced out of the capsule by the actuation mechanism such that the tissue penetrating member is advanced through an intestinal wall of the patient and inserted into a peritoneal cavity of the patient after swallowing of the swallowable device to deliver the liquid therapeutic agent preparation into the peritoneal cavity.

### Claim 53 (depends on 52)

The method of claim 52, wherein the tissue penetrating member has a column strength in a range of about 1 to 20 lbs.

### Claim 54 (depends on 52)

The method of claim 52, wherein the tissue penetrating member is structured as a shaft having a pointed end.

### Claim 55 (depends on 52)

The method of claim 52, wherein the clotting factor disorder comprises hemophilia A and the clotting factor comprises Factor VIII (F8) or a Factor VIII analogue (F8A).

### Claim 56 (depends on 52)

The method of claim 52, wherein the clotting factor disorder comprises one or both of Factor VII deficiency and Glanzmann's Thrombasthenia and the clotting factor comprises Factor VII (F7) or a Factor VII analogue (F7A).

### Claim 57 (depends on 52)

The method of claim 52, wherein the clotting factor disorder comprises hemophilia B and the clotting factor comprises Factor IX (F9) or a Factor IX analogue (F9A).

### Claim 58 (depends on 52)

The method of claim 52, wherein the clotting factor disorder comprises Factor X deficiency and the clotting factor comprises Factor X (F10) or a Factor X analogue (F10A).

### Claim 59 (depends on 52)

The method of claim 52, wherein the tissue penetrating member comprises a hollow needle.

### Claim 60 (depends on 59)

The method of claim 59, wherein the hollow needle comprises a lumen containing the liquid therapeutic agent preparation.

### Claim 61 (depends on 59)

The method of claim 59, wherein the actuation mechanism is actuated to advance the tissue penetrating member through the intestinal wall of the patient and insert the tissue penetrating member into the peritoneal cavity to deliver the liquid therapeutic agent preparation through the hollow needle into the peritoneal cavity.

### Claim 62 (depends on 61)

The method of claim 61, wherein the actuating mechanism is further configured to withdraw the hollow needle from the intestinal wall.

### Claim 63 (depends on 52)

The method of claim 52, wherein the liquid therapeutic agent preparation is contained within a reservoir disposed in the capsule.

### Claim 64 (depends on 52)

The method of claim 52, wherein the tissue penetrating member comprises a biodegradable material.

### Claim 65 (depends on 64)

The method of claim 64, wherein the biodegradable material is configured to degrade in serosal fluids of the peritoneal cavity.

### Claim 66 (depends on 52)

The method of claim 52, wherein the capsule comprises a biodegradable material configured to degrade by contact with fluids in the gastrointestinal (GI) tract of the patient.

### Claim 67 (depends on 52)

The method of claim 52, wherein the capsule comprises an outer coating or a layer configured to degrade at a selected pH in the GI tract of the patient.

### Claim 68 (depends on 52)

The method of claim 52, wherein the actuation mechanism comprises an expandable member.

### Claim 69 (depends on 68)

The method of claim 68, wherein the expandable member comprises an expandable balloon.

### Claim 70 (depends on 69)

The method of claim 69, wherein the expandable member comprises a first compartment comprising a first reactant and a second compartment comprising a second reactant, the first compartment and the second compartment separated by a releasable valve which releases upon exposure to fluid in the GI tract.

### Claim 71 (depends on 70)

The method of claim 70, wherein when the releasable valve releases the first and second reactants mix to produce a gas to increase a pressure in the expandable balloon to advance the tissue penetrating member from the capsule.
